|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:abbreviation
|
gptkb:BCG
|
|
gptkbp:administeredBy
|
intradermal injection
birth (in high TB prevalence countries)
|
|
gptkbp:ATCCode
|
gptkb:J07AN01
|
|
gptkbp:boosterRecommended
|
no
|
|
gptkbp:contains
|
gptkb:live_attenuated_Mycobacterium_bovis
|
|
gptkbp:contraindication
|
pregnancy
immunocompromised individuals
|
|
gptkbp:crossProtection
|
buruli ulcer (partial)
leprosy (partial)
|
|
gptkbp:developedBy
|
gptkb:Camille_Guérin
gptkb:Albert_Calmette
|
|
gptkbp:doseForm
|
lyophilized powder
|
|
gptkbp:duration
|
10-20 years (variable)
|
|
gptkbp:effect
|
variable
|
|
gptkbp:foundIn
|
gptkb:Brazil
gptkb:India
gptkb:Japan
many countries worldwide
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BCG vaccine (human use)
|
|
gptkbp:immunityType
|
cell-mediated
|
|
gptkbp:includedIn
|
gptkb:Expanded_Programme_on_Immunization_(EPI)
|
|
gptkbp:introducedIn
|
1921
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
various pharmaceutical companies
|
|
gptkbp:namedAfter
|
gptkb:Bacillus_Calmette-Guérin
|
|
gptkbp:notEffectiveAgainst
|
gptkb:latent_tuberculosis_infection
adult pulmonary tuberculosis (variable)
|
|
gptkbp:notUsedInCountries
|
Netherlands (routine use not recommended)
United States (routine use not recommended)
|
|
gptkbp:pregnancyCategory
|
contraindicated
|
|
gptkbp:protectedBy
|
miliary tuberculosis
tuberculous meningitis in children
|
|
gptkbp:reconstitutedWith
|
sterile saline
|
|
gptkbp:routeOfAdministration
|
intradermal
|
|
gptkbp:sideEffect
|
lymphadenitis
injection site ulceration
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:usedFor
|
bladder cancer immunotherapy
prevention of tuberculosis
|
|
gptkbp:usedIn
|
children
newborns
adults at risk
|
|
gptkbp:vaccineType
|
live attenuated bacterial vaccine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:WHOPrequalified
|
yes
|
|
gptkbp:bfsParent
|
gptkb:BCG_vaccine_(limited_use_in_cattle)
|
|
gptkbp:bfsLayer
|
6
|